Saint Luke's Newsroom
Sep. 6, 2023
KMBC: Doctor, Fans Discuss Injury to Chiefs Tight End Travis Kelce
KMBC talked to Dr. Wes Frevert about what this type of injury typically means for an athlete.
Sep. 1, 2023
Becker's Hospital Review: Saint Luke's Expands Hospital In Your Home Program
Saint Luke's Health System has expanded its hospital-at-home program to its Overland Park-based Saint Luke's South Hospital.
Sep. 1, 2023
FOX4: Saint Luke's Expands Hospital In Your Home Program to Serve Kansas Patients
Saint Luke's has expanded its Hospital In Your Home program, now available to Saint Luke's South Hospital and residents of Kansas.
Sep. 1, 2023
The New England Journal of Medicine Podcast: Obesity and Heart Failure
The NEJM Podcast looks at obesity and how it’s been neglected as a key to diagnosing and treating major diseases, including heart failure.
Aug. 31, 2023
KMBC: Kansas City Current Players Visit Saint Luke's Hospital Cancer Patients for Support
Leading up to the KC Kicks Cancer match, the players talked with patients about their journey and the importance of preventive screenings.
Aug. 30, 2023
KSHB: What KC Area Doctors Want You to Know About Eris, the Latest COVID-19 Variant
KSHB talked to Dr. Sarah Boyd about what people should know about the new variant of COVID-19.
Aug. 28, 2023
New York Times: Obesity Treatment Relieves Heart Failure Symptoms, Drugmaker’s Study Finds
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.
Aug. 28, 2023
Nature Medicine: Semaglutide in HFpEF Across Obesity Class and by Body Weight Reduction: a Prespecified Analysis of the STEP-HFpEF Trial
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF).
Aug. 26, 2023
CBS Evening News: Study Shows Wegovy May Reduce Risk of Heart Failure
The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.